Supporting strategic fundamental research in life sciences through carefully selected projects from universities in the Wallonia-Brussels Federation, with a view to transforming their discoveries into industrial applications.
François Fuks (WELBIO – ULB) and his team demonstrated the role of the regulation of RNA epigenetics by the FTO enzyme in the development of cancer metastasis.
From disruptive research of scientific founder Benoit Vanhollebeke (WELBIO - ULB) to the development of blood-brain barrier pharmaceuticals aiming at repairing neurovascular function and neurodegenerative diseases.
Patrice Cani (WELBIO - UCLouvain) describes the properties displayed by D. welbionis, a new bacterium present in 70% of the population, that open the doors for potential treatment for type 2 diabetes, obesity and inflammatory diseases.
WELBIO's essential mission is to support top level fundamental research in life sciences. This mission is currently integrated with the Fonds de la Recherche Fondamentale Stratégique (F.R.S.-FNRS).
WELBIO supports fundamental research with the view to translate scientific results into industrial applications. Through valorisation committees, a sustained focus is kept on the protection of intellectual property in particular.
The WELBIO Bridge Fund is a research funding instrument intended for WELBIO investigators and designed to bridge the gap between early stage research and the development of a competitive package for the next funding step
With its focus on life sciences, WELBIO holds a unique position between fundamental research in all fields and applied biomedical research sur les sciences du vivant. WELBIO works closely with the FRNS and BioWin in particular.
